ABSTRACT NUMBER: ESOC2026A2308 GLP-1 OR DUAL GIP/GLP-1 RECEPTOR AGONIST IN ACUTE ISCHAEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PRE-CLINICAL STUDIES
Sara Eltirafi, Harry Keevil, Viswesh Anand, Tim England · 2026
Read ABSTRACT NUMBER: ESOC2026A2308 GLP-1 OR DUAL GIP/GLP-1 RECEPTOR AGONIST IN ACUTE ISCHAEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PRE-CLINICAL STUDIES by Sara Eltirafi, Harry Keevil, Viswesh Anand, Tim England (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13145916.txt.
Description
Sara Eltirafi and co-authors pool in this 2026 conference review the animal evidence on diabetes drugs as shields for the stroked brain. GLP-1 receptor agonists, and newer dual GIP/GLP-1 drugs, are licensed for diabetes and weight, and may also protect neurons. The team gathered forty-six publications covering 141 pre-clinical stroke studies.
Against controls, treated rodents, diabetic or not, showed much smaller dead brain areas a day or two after stroke. Movement and nerve scores improved by two weeks. Almost all work used GLP-1 drugs alone, so dual agents, females, and larger animals remain gaps. Signs of publication bias also temper the cheer. Human trials remain the missing step for now.
Catalog record
| CREATOR | Sara Eltirafi, Harry Keevil, Viswesh Anand, Tim England |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |